These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 16132345)

  • 1. Human multidrug resistance associated protein 4 confers resistance to camptothecins.
    Tian Q; Zhang J; Tan TM; Chan E; Duan W; Chan SY; Boelsterli UA; Ho PC; Yang H; Bian JS; Huang M; Zhu YZ; Xiong W; Li X; Zhou S
    Pharm Res; 2005 Nov; 22(11):1837-53. PubMed ID: 16132345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topotecan is a substrate for multidrug resistance associated protein 4.
    Tian Q; Zhang J; Chan SY; Tan TM; Duan W; Huang M; Zhu YZ; Chan E; Yu Q; Nie YQ; Ho PC; Li Q; Ng KY; Yang HY; Wei H; Bian JS; Zhou SF
    Curr Drug Metab; 2006 Jan; 7(1):105-18. PubMed ID: 16454695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P.
    Chen ZS; Furukawa T; Sumizawa T; Ono K; Ueda K; Seto K; Akiyama SI
    Mol Pharmacol; 1999 May; 55(5):921-8. PubMed ID: 10220571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
    Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
    Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.
    Norris MD; Smith J; Tanabe K; Tobin P; Flemming C; Scheffer GL; Wielinga P; Cohn SL; London WB; Marshall GM; Allen JD; Haber M
    Mol Cancer Ther; 2005 Apr; 4(4):547-53. PubMed ID: 15827327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
    Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
    Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines.
    Chu XY; Suzuki H; Ueda K; Kato Y; Akiyama S; Sugiyama Y
    J Pharmacol Exp Ther; 1999 Feb; 288(2):735-41. PubMed ID: 9918583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.
    Yokoo K; Hamada A; Watanabe H; Matsuzaki T; Imai T; Fujimoto H; Masa K; Imai T; Saito H
    Drug Metab Dispos; 2007 Sep; 35(9):1511-7. PubMed ID: 17537871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
    Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
    Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
    Bissery MC; Vrignaud P; Lavelle F; Chabot GG
    Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
    Rajendra R; Gounder MK; Saleem A; Schellens JH; Ross DD; Bates SE; Sinko P; Rubin EH
    Cancer Res; 2003 Jun; 63(12):3228-33. PubMed ID: 12810652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
    Mishra MN; Vangara KK; Palakurthi S
    Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
    Yamamoto W; Verweij J; de Bruijn P; de Jonge MJ; Takano H; Nishiyama M; Kurihara M; Sparreboom A
    Anticancer Drugs; 2001 Jun; 12(5):419-32. PubMed ID: 11395570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells.
    Lee K; Klein-Szanto AJ; Kruh GD
    J Natl Cancer Inst; 2000 Dec; 92(23):1934-40. PubMed ID: 11106685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.
    Jansen WJ; Hulscher TM; van Ark-Otte J; Giaccone G; Pinedo HM; Boven E
    Br J Cancer; 1998; 77(3):359-65. PubMed ID: 9472629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Camptothecin analogues with enhanced antitumor activity at acidic pH.
    Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
    Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
    Ma J; Maliepaard M; Nooter K; Loos WJ; Kolker HJ; Verweij J; Stoter G; Schellens JH
    Br J Cancer; 1998 May; 77(10):1645-52. PubMed ID: 9635842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells.
    Chen ZS; Sumizawa T; Furukawa T; Ono K; Tani A; Komatsu M; Akiyama S
    Cancer Lett; 1999 Apr; 138(1-2):13-22. PubMed ID: 10378768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
    van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
    Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
    Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
    Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.